Spyre Therapeutics Announces 12-Week Induction Data From Part A Of Phase 2 SKYLINE Study Of SPY002 To Treat Active Ulcerative Colitis Meets Primary Endpoint; SPY002 Well Tolerated With Consistent Safety Profile

뉴스 본문을 불러오고 있어요.

Spyre Therapeutics Announces 12-Week Induction Data From Part A Of Phase 2 SKYLINE Study Of SPY002 To Treat Active Ulcerative Colitis Meets Primary Endpoint; SPY002 Well Tolerated With Consistent Safety Profile | 웨이프 WAPE

Spyre Therapeutics Announces 12-Week Induction Data From Part A Of Phase 2 SKYLINE Study Of SPY002 To Treat Active Ulcerative Colitis Meets Primary Endpoint; SPY002 Well Tolerated With Consistent Safety Profile

기사 요약

관련 종목

댓글 —